# RETROSPECTIVE DRUG UTILIZATION REVIEW REPORT
## August 2010

<table>
<thead>
<tr>
<th>MODULE</th>
<th>DRUG INTERACTION</th>
<th>DUPLICATION OF THERAPY</th>
<th>DRUG-DISEASE PRECAUTIONS</th>
<th>DOSING &amp; DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total # of messages</td>
<td>51,463</td>
<td>63,940</td>
<td>1,044,192</td>
<td>25,044</td>
</tr>
<tr>
<td><strong>Limits applied</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Established, Major, Males and Females, Age 19-35</td>
<td></td>
<td>Males and Females, Anorexiants/Stimulants, Age 5-6</td>
<td>Contraindicated, Pregnancy, Males and Females, Age 19-35</td>
<td>High Dose, Males and Females, Age 0-150, Androgens</td>
</tr>
<tr>
<td>Total # of messages after limits were applied</td>
<td>53</td>
<td>152</td>
<td>1,129 (229)</td>
<td>13</td>
</tr>
<tr>
<td>Total # of members reviewed</td>
<td>53</td>
<td>146</td>
<td>229</td>
<td>13</td>
</tr>
</tbody>
</table>

## LETTERS

<table>
<thead>
<tr>
<th>Category</th>
<th>Prescribers</th>
<th>Pharmacies</th>
<th>Total Letters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Interaction</td>
<td>11</td>
<td>6</td>
<td>17</td>
</tr>
<tr>
<td>Duplication of Therapy</td>
<td>21</td>
<td>6</td>
<td>27</td>
</tr>
<tr>
<td>Drug-Disease Precautions</td>
<td>13</td>
<td>11</td>
<td>24</td>
</tr>
<tr>
<td>Dosing &amp; Duration</td>
<td>10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Total Letters Sent</td>
<td>55</td>
<td>23</td>
<td>78</td>
</tr>
</tbody>
</table>
PRIOR AUTHORIZATION ACTIVITY REPORT: September 2010

- Approved: 5,210 (50%)
- Denied: 458 (4%)
- Incomplete: 4,805 (46%)

PA totals include overrides
PRIOR AUTHORIZATION REPORT: September 2009 – September 2010

PA totals include overrides
# Prior Authorization Activity

**September 2010**

<table>
<thead>
<tr>
<th>Drug Category</th>
<th>Total</th>
<th>Approved</th>
<th>Denied</th>
<th>Incomplete</th>
<th>Average Length of Approvals in Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advair/Symbicort</td>
<td>467</td>
<td>219</td>
<td>10</td>
<td>238</td>
<td>358</td>
</tr>
<tr>
<td>Amitiza</td>
<td>26</td>
<td>6</td>
<td>2</td>
<td>18</td>
<td>183</td>
</tr>
<tr>
<td>Anti-Ulcer</td>
<td>463</td>
<td>118</td>
<td>35</td>
<td>310</td>
<td>126</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>321</td>
<td>114</td>
<td>9</td>
<td>198</td>
<td>339</td>
</tr>
<tr>
<td>Antihistamine</td>
<td>393</td>
<td>204</td>
<td>10</td>
<td>179</td>
<td>334</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>122</td>
<td>46</td>
<td>3</td>
<td>73</td>
<td>347</td>
</tr>
<tr>
<td>Antimigraine</td>
<td>71</td>
<td>8</td>
<td>5</td>
<td>58</td>
<td>182</td>
</tr>
<tr>
<td>Atypical Antipsychotics</td>
<td>754</td>
<td>373</td>
<td>10</td>
<td>371</td>
<td>346</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>102</td>
<td>34</td>
<td>6</td>
<td>62</td>
<td>283</td>
</tr>
<tr>
<td>Bladder Control</td>
<td>74</td>
<td>18</td>
<td>3</td>
<td>53</td>
<td>360</td>
</tr>
<tr>
<td>Brovana (Arformoterol)</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>361</td>
</tr>
<tr>
<td>Byetta</td>
<td>13</td>
<td>5</td>
<td>0</td>
<td>8</td>
<td>343</td>
</tr>
<tr>
<td>Eliadel/Protopic</td>
<td>56</td>
<td>20</td>
<td>7</td>
<td>29</td>
<td>106</td>
</tr>
<tr>
<td>ESA</td>
<td>189</td>
<td>139</td>
<td>6</td>
<td>44</td>
<td>63</td>
</tr>
<tr>
<td>Fibric Acid Derivatives</td>
<td>22</td>
<td>1</td>
<td>3</td>
<td>18</td>
<td>358</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>115</td>
<td>50</td>
<td>3</td>
<td>62</td>
<td>344</td>
</tr>
<tr>
<td>Forteo</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>355</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>14</td>
<td>4</td>
<td>0</td>
<td>10</td>
<td>360</td>
</tr>
<tr>
<td>Growth Hormones</td>
<td>63</td>
<td>49</td>
<td>5</td>
<td>9</td>
<td>170</td>
</tr>
<tr>
<td>HFA Rescue Inhalers</td>
<td>107</td>
<td>35</td>
<td>7</td>
<td>65</td>
<td>283</td>
</tr>
<tr>
<td>Insomnia</td>
<td>110</td>
<td>29</td>
<td>5</td>
<td>76</td>
<td>178</td>
</tr>
<tr>
<td>Misc Analgesics</td>
<td>35</td>
<td>3</td>
<td>16</td>
<td>16</td>
<td>209</td>
</tr>
<tr>
<td>Muscle Relaxant</td>
<td>138</td>
<td>39</td>
<td>45</td>
<td>54</td>
<td>98</td>
</tr>
<tr>
<td>Nasal Allergy</td>
<td>324</td>
<td>111</td>
<td>27</td>
<td>186</td>
<td>139</td>
</tr>
<tr>
<td>NSAIDS</td>
<td>161</td>
<td>32</td>
<td>17</td>
<td>112</td>
<td>284</td>
</tr>
<tr>
<td>Ocular Allergy</td>
<td>26</td>
<td>5</td>
<td>1</td>
<td>20</td>
<td>134</td>
</tr>
<tr>
<td>Ocular Antibiotics</td>
<td>88</td>
<td>51</td>
<td>1</td>
<td>36</td>
<td>14</td>
</tr>
<tr>
<td>Opioid Analgesic</td>
<td>290</td>
<td>121</td>
<td>12</td>
<td>157</td>
<td>216</td>
</tr>
<tr>
<td>Other</td>
<td>705</td>
<td>197</td>
<td>57</td>
<td>451</td>
<td>177</td>
</tr>
<tr>
<td>Otic Antibiotic</td>
<td>124</td>
<td>86</td>
<td>0</td>
<td>38</td>
<td>15</td>
</tr>
<tr>
<td>Pediculicides</td>
<td>129</td>
<td>71</td>
<td>5</td>
<td>53</td>
<td>16</td>
</tr>
<tr>
<td>Plavix</td>
<td>206</td>
<td>131</td>
<td>2</td>
<td>73</td>
<td>330</td>
</tr>
<tr>
<td>Qualaquin (Quinine)</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Singular</td>
<td>965</td>
<td>499</td>
<td>25</td>
<td>441</td>
<td>274</td>
</tr>
<tr>
<td>Smoking Cessation</td>
<td>59</td>
<td>19</td>
<td>4</td>
<td>36</td>
<td>59</td>
</tr>
<tr>
<td>Statins</td>
<td>371</td>
<td>72</td>
<td>12</td>
<td>287</td>
<td>330</td>
</tr>
<tr>
<td>Stimulant</td>
<td>1,471</td>
<td>921</td>
<td>39</td>
<td>511</td>
<td>241</td>
</tr>
<tr>
<td>Symlin</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Synagis</td>
<td>18</td>
<td>0</td>
<td>0</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Topical Antibiotics</td>
<td>22</td>
<td>7</td>
<td>0</td>
<td>15</td>
<td>40</td>
</tr>
<tr>
<td>Topical Antifungals</td>
<td>19</td>
<td>2</td>
<td>2</td>
<td>15</td>
<td>103</td>
</tr>
<tr>
<td>Ultram ER and ODT</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Xopenex Nebs</td>
<td>35</td>
<td>18</td>
<td>3</td>
<td>14</td>
<td>326</td>
</tr>
<tr>
<td>Zetia (Ezetimibe)</td>
<td>17</td>
<td>9</td>
<td>1</td>
<td>7</td>
<td>361</td>
</tr>
<tr>
<td>Emergency PAs</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>8,710</td>
<td>3,878</td>
<td>400</td>
<td>4,432</td>
<td></td>
</tr>
</tbody>
</table>
### Overrides

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand</th>
<th>Dosage Change</th>
<th>High Dose</th>
<th>IHS-Brand</th>
<th>Ingredient Duplication</th>
<th>Lost/Broken Rx</th>
<th>NDC vs Age</th>
<th>Nursing Home Issue</th>
<th>Other</th>
<th>Quantity vs. Days Supply</th>
<th>Stolen</th>
<th>Wrong D.S. on Previous Rx</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>52</td>
<td>26</td>
<td>5</td>
<td>21</td>
<td>3</td>
<td>128</td>
<td>23</td>
<td>101</td>
<td>32</td>
<td>829</td>
<td>6</td>
<td>1</td>
<td>1,766</td>
</tr>
<tr>
<td></td>
<td>538</td>
<td>502</td>
<td>7</td>
<td>29</td>
<td>9</td>
<td>120</td>
<td>23</td>
<td>87</td>
<td>26</td>
<td>490</td>
<td>6</td>
<td>3</td>
<td>1,334</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>217</td>
<td>0</td>
<td>0</td>
<td>14</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>36</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>49</td>
<td>46</td>
<td>0</td>
<td>3</td>
<td>176</td>
<td>2</td>
<td>0</td>
<td>14</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>374</td>
</tr>
<tr>
<td><strong>Overrides Total</strong></td>
<td><strong>1,766</strong></td>
<td><strong>1,334</strong></td>
<td><strong>58</strong></td>
<td><strong>374</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total Regular PAs + Overrides**: 10,476 5,212 458 4,806

### Denial Reasons

- Unable to verify required trials: 3,289
- Lack required information to process request: 1,459
- Does not meet established criteria: 482
- Not an FDA approved indication/diagnosis: 3
- Drug Not Deemed Medically Necessary: 1
- Considered duplicate therapy. Member has a prior authorization for similar medication: 1

### Other

- Duplicate Requests: 995
- Letters: 1,111
- No Process: 1,107
- Changes to existing PAs: 506
CALL VOLUME MONTHLY REPORT:
September 2009 – September 2010

TOTAL CALLS

Trend

09-09: 12,700
10-09: 13,129
11-09: 11,631
12-09: 11,764
01-10: 11,390
02-10: 11,014
03-10: 12,779
04-10: 13,779
05-10: 12,570
06-10: 11,890
07-10: 15,555
08-10: 14,301
09-10: 16,755
10-10: 16,600
FY2010 Annual Review of Growth Hormones

Oklahoma Health Care Authority
October 2010

Current Indications for Growth Hormone

Covered Indications
- Classic hGH Deficiency
- Short Stature (including Prader-Willi Syndrome)
- Short Stature associated with Chronic Renal Insufficiency
- Small for Gestational Age (SGA)
- Turner’s Syndrome or 45 X, 46 XY Mosaicism in males
- Hypoglycemia associated with hGH Insufficiency
- AIDS Wasting (Serostim only)
- SHOX (short stature homeobox-containing gene) Deficiency

Trends in Utilization of Growth Hormones

Utilization of Growth Hormones during Fiscal Year 2010

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Members</th>
<th>Claims</th>
<th>Cost</th>
<th>Cost/Claim</th>
<th>Per-diem</th>
<th>Units</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>216</td>
<td>1,566</td>
<td>$3,750,634.44</td>
<td>$2,395.04</td>
<td>$83.09</td>
<td>11,403</td>
<td>45,142</td>
</tr>
<tr>
<td>2010</td>
<td>213</td>
<td>1,634</td>
<td>$4,075,790.90</td>
<td>$2,494.36</td>
<td>$86.43</td>
<td>11,012</td>
<td>47,157</td>
</tr>
<tr>
<td>% Change</td>
<td>-1.40%</td>
<td>4.30%</td>
<td>8.70%</td>
<td>4.10%</td>
<td>4.00%</td>
<td>-3.40%</td>
<td>4.50%</td>
</tr>
<tr>
<td>Change</td>
<td>-3</td>
<td>68</td>
<td>$325,156.46</td>
<td>$99.32</td>
<td>$3.34</td>
<td>-391</td>
<td>2,015</td>
</tr>
</tbody>
</table>

There was no use of Zorbtive™, Tev-tropin® or either of the IGF-1 analogs, Iplex™ orIncrelex™.

Market Share of Growth Hormone Products

- NORDITROPIN, 38.81%
- HUMATROPE, 15.89%
- GENOTROPIN, 10.71%
- SEROSTIM, 1.37%
- SAIZEN, 0.80%
- OMNITROPE, 0.02%
- NUTROPINAQ, 24.42%
- NUTROPIN, 8.00%
## Utilization Details of Growth Hormones during Fiscal Year 2010

<table>
<thead>
<tr>
<th>BRAND NAME</th>
<th>CLAIMS</th>
<th>UNITS</th>
<th>DAYS</th>
<th>MEMBERS</th>
<th>COST</th>
<th>CLAIMS/MEMBER</th>
<th>COST/MG</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORDITROPIN INJ 10/1.5ML</td>
<td>260</td>
<td>1,178</td>
<td>7,907</td>
<td>32</td>
<td>$490,154.44</td>
<td>8.13</td>
<td>65.06</td>
</tr>
<tr>
<td>NORDITROPIN INJ 15/1.5ML</td>
<td>216</td>
<td>1,156</td>
<td>6,131</td>
<td>37</td>
<td>$713,529.71</td>
<td>5.84</td>
<td>65.06</td>
</tr>
<tr>
<td>NUTROPIN AQ INJ 10MG/2ML</td>
<td>187</td>
<td>1,286</td>
<td>5,394</td>
<td>25</td>
<td>$409,890.16</td>
<td>7.48</td>
<td>65.04</td>
</tr>
<tr>
<td>NUTROPIN AQ INJ 20MG/2ML</td>
<td>146</td>
<td>898</td>
<td>4,150</td>
<td>19</td>
<td>$585,371.97</td>
<td>7.68</td>
<td>65.19</td>
</tr>
<tr>
<td>HUMATROPE INJ 6MG</td>
<td>109</td>
<td>332</td>
<td>3,095</td>
<td>19</td>
<td>$129,925.64</td>
<td>5.74</td>
<td>65.22</td>
</tr>
<tr>
<td>NORDITROPIN INJ 5/1.5ML</td>
<td>105</td>
<td>617</td>
<td>3,139</td>
<td>15</td>
<td>$133,893.14</td>
<td>7.5</td>
<td>65.10</td>
</tr>
<tr>
<td>GENOTROPIN INJ 13.8MG</td>
<td>94</td>
<td>276</td>
<td>2,672</td>
<td>11</td>
<td>$212,142.28</td>
<td>8.55</td>
<td>64.05</td>
</tr>
<tr>
<td>NUTROPIN INJ 10MG</td>
<td>86</td>
<td>453</td>
<td>2,480</td>
<td>10</td>
<td>$272,219.45</td>
<td>8.6</td>
<td>62.87</td>
</tr>
<tr>
<td>NORDITROPIN INJ 30/3ML</td>
<td>73</td>
<td>372</td>
<td>1,951</td>
<td>18</td>
<td>$243,919.95</td>
<td>4.06</td>
<td>65.57</td>
</tr>
<tr>
<td>HUMATROPE INJ 12MG</td>
<td>68</td>
<td>165</td>
<td>1,919</td>
<td>10</td>
<td>$121,105.13</td>
<td>6.8</td>
<td>65.04</td>
</tr>
<tr>
<td>HUMATROPE INJ 24MG</td>
<td>49</td>
<td>142</td>
<td>1,445</td>
<td>7</td>
<td>$222,772.21</td>
<td>7.5</td>
<td>65.37</td>
</tr>
<tr>
<td>NUTROPIN INJ 5MG</td>
<td>46</td>
<td>230</td>
<td>1,272</td>
<td>4</td>
<td>$53,656.32</td>
<td>11.5</td>
<td>67.35</td>
</tr>
<tr>
<td>GENOTROPIN INJ 1MG</td>
<td>36</td>
<td>1,008</td>
<td>1,008</td>
<td>5</td>
<td>$65,309.46</td>
<td>7.2</td>
<td>64.89</td>
</tr>
<tr>
<td>HUMATROPE INJ 5MG</td>
<td>43</td>
<td>533</td>
<td>1,278</td>
<td>7</td>
<td>$173,429.11</td>
<td>6</td>
<td>65.07</td>
</tr>
<tr>
<td>GENOTROPIN INJ 5.8MG</td>
<td>23</td>
<td>88</td>
<td>681</td>
<td>3</td>
<td>$28,544.06</td>
<td>7.67</td>
<td>64.87</td>
</tr>
<tr>
<td>GENOTROPIN INJ 2MG</td>
<td>18</td>
<td>504</td>
<td>506</td>
<td>2</td>
<td>$64,522.36</td>
<td>9</td>
<td>63.76</td>
</tr>
<tr>
<td>SAIZEN INJ 8.8MG</td>
<td>13</td>
<td>62</td>
<td>392</td>
<td>2</td>
<td>$32,482.37</td>
<td>6.5</td>
<td>59.53</td>
</tr>
<tr>
<td>GENOTROPIN INJ 0.6MG</td>
<td>13</td>
<td>364</td>
<td>364</td>
<td>3</td>
<td>$14,079.29</td>
<td>4.33</td>
<td>64.47</td>
</tr>
<tr>
<td>GENOTROPIN INJ 1.2MG</td>
<td>12</td>
<td>336</td>
<td>336</td>
<td>3</td>
<td>$26,057.14</td>
<td>4</td>
<td>64.63</td>
</tr>
<tr>
<td>GENOTROPIN INJ 0.8MG</td>
<td>12</td>
<td>336</td>
<td>336</td>
<td>3</td>
<td>$17,194.53</td>
<td>4</td>
<td>63.89</td>
</tr>
<tr>
<td>GENOTROPIN INJ 0.2MG</td>
<td>10</td>
<td>280</td>
<td>280</td>
<td>2</td>
<td>$3,613.48</td>
<td>5</td>
<td>64.53</td>
</tr>
<tr>
<td>GENOTROPIN INJ 0.4MG</td>
<td>7</td>
<td>196</td>
<td>196</td>
<td>2</td>
<td>$5,212.83</td>
<td>3.5</td>
<td>66.49</td>
</tr>
<tr>
<td>SEROSTIM INJ 6MG</td>
<td>7</td>
<td>196</td>
<td>200</td>
<td>1</td>
<td>$55,871.70</td>
<td>7</td>
<td>47.51</td>
</tr>
<tr>
<td>OMNITROPE INJ 5/1.5ML</td>
<td>1</td>
<td>45</td>
<td>25</td>
<td>1</td>
<td>$794.17</td>
<td>1</td>
<td>52.94</td>
</tr>
</tbody>
</table>

Totals: 1,634 | 11,013 | 47,157 | 213* | $4,075,790.90 | 7.67 | 63.48**

*Unduplicated Members  **Average cost/mg

## Demographics of Members Utilizing Growth Hormone during Fiscal Year 2010

![Chart showing demographics of members utilizing growth hormone by age group and gender.](chart.png)
Prior Authorization of Growth Hormones during Fiscal Year 2010

A total of 533 petitions were submitted for growth hormone in FY10.

![Pie chart showing percentages of approved, denied, and incomplete petitions.]

Denied, 30, 6%
Approved, 442, 83%
Incomplete, 61, 11%

Market News

- March 2010 – Novo Nordisk, Inc., introduced Norditropin Flexpro prefilled pen device. The EAC (estimated acquisition cost) of this product is $69.90/mg, compared with $65.20 for the previous device.

Trends across the United States

Random review of other states’ Medicaid program elicited the following findings that differed from the SoonerCare Criteria:

Alabama – Does not cover Idiopathic Short Stature (ISS) or Small for Gestational Age (SGA); height requirement <5%; clonidine not acceptable as provocative test; growth hormone-releasing hormone (GHRH) is acceptable. Adults are required to take insulin tolerance test (ITT), unless contraindicated. Normal thyroid function required for all indications.

Alaska – ISS not covered; height velocity <10th percentile of normal for age/sex and tracked over one year. Prader-Willi confirmed by genetic testing.

Arkansas – ISS not covered, septo-optic dysplasia is acceptable diagnosis; no height or velocity requirements. Panhypopituitarism proven by two pituitary hormone replacements (thyroid, hydrocortisone, estrogen, or testosterone).

California – ISS not covered; two provocative tests below 7 ng/ml. If stim results 7-12 ng/ml, have documented delayed growth rate for age 4.5 cm/yr or less for male 0-12 years and female 0-10 years; <8-10 cm/yr if pubertal changes.

Delaware – ISS not covered. Growth velocity <7 cm/yr for 3 years and under, <5 cm/yr for 4 years and up. Height <5th percentile. Covered until final height or epiphyseal closure.

Georgia – predicted height <3rd percentile based on bone age. Continue if growth velocity doubled or increased by 3 cm/yr in the first year,
Idaho – ISS, SGA, SHOX not covered; levodopa and arginine <7 ng/ml, ITT <7 ng/ml “an equivalent diagnostic test” for documentation of deficiency; Height velocity <10th percentile for age/sex tracked over at least one year; increase in height velocity of at least 2 cm/yr over one year

Iowa – ISS not covered

Kansas – ISS, SGA not covered; normal thyroid functions before testing; height velocity <25th percentile for age for all indications, height <5th percentile for Turner, Noonan, or Prader-Willi also acceptable. Discontinue if growth velocity <2 cm, noncompliant, or failure to show changes in body composition, lipid profile, or growth rate in PWS

Maryland – ISS not covered. Adults with childhood onset GHD or additional pituitary hormone deficits require 1 stim test, all others (adults and children) require 2. ITT required unless contraindicated. Arginine, glucagon, GHRH, L-dopa and combinations of them acceptable; not clonidine. Adults require bone density testing. For chronic renal insufficiency, only IGF-1 required. Continue until 25th percentile achieved, Height velocity >2.5 cm/yr over pretreatment rate

Minnesota – ISS, SGA not covered, “decreasing velocity relative to physical and chronological age”, height <5th percentile for age or absolute height -2.25 SD, ISS not covered, but may be reconsidered if the patient undergoes a 6 month trial of GH supplied by manufacturer and shows restoration of normal growth and development. Continue if growth velocity increases by 2 cm/yr in first year and >2.5 cm/yr. Covered height 5’6” for males, 5’1” for females.

Montana – ISS, SGA not covered

Nebraska – ISS, SGA not covered; growth velocity <4 cm/yr, thyroid and cortical normal or replaced, bone age >2 SD delayed

Nevada – height <5th percentile, bone age >2 years delayed.

New Hampshire – height velocity over 1 year >1 SD below the mean for chronological age; if >2 years old, -0.5SD height loss over a year.

North Carolina – ISS, SGA not covered; bone age -2SD below mean for age/sex; accept two provocative test or IGF-1 or IGFBP-3 level. Cont if height velocity >4.5 cm/yr (prepubertal) or >2.5 cm/yr (postpubertal)

Oregon – Adults not covered. No lab or height requirements. Epiphyses open. Continue tx if height velocity >2.5 cm/yr.

Pennsylvania – Growth velocity -2-3SD below age related mean, bone age -2SD delay; SGA if no catch up by 3 years of age with height -2SD below the mean; Cont if height velocity >4.5 cm/yr (prepubertal) or >2.5 cm/yr (postpubertal)

Vermont – ISS not covered. Propranolol included as provocative test. All available provocative tests acceptable for children and adults – children x2, adults x1

West Virginia – ISS, SGA not covered. Neurosecretory growth retardation included with mixed or normal provocative test and IGF-1 levels <50th percentile for chronological age.

Wyoming – ISS, short stature of chronic renal insufficiency not covered
Discussion of Growth Hormone Criteria

The following is the current growth hormone coverage criteria. The black type is the current criteria, the red sections are the recommended changes or additions to the current criteria received after consultation with an adult and pediatric endocrinologist. $ indicates increased expenditures may occur if changes are implemented.

COVERED INDICATIONS

- Classic hGH Deficiency
- Short Stature (including Prader-Willi Syndrome)
- Short Stature associated with chronic renal insufficiency
- Small for Gestational Age (SGA)
- Turner’s Syndrome or 45 X, 46 XY mosaicism in males
- Hypoglycemia associated with hGH insufficiency
- AIDS wasting (Serostim only)
- SHOX (short stature homeobox-containing gene) deficiency

Covered indications

Childhood indications (prior to epiphyseal closure$)

Classic hGH deficiency as determined by childhood hGH stimulation tests outlined below

1) History of pituitary or hypothalamic injury due to tumor, trauma, surgery, irradiation, hemorrhage or infarction or a congenital anomaly and
   a. ≥ 3 pituitary hormones deficient and IGF-1 ≤ 2.5 percentile
   b. 0,1,or 2 hormones deficient and IGF-1 < 50th percentile failure of a growth hormone stimulation test as outlined below
2) Children with height <2.25 SD for mean for age and MRI evidence for pituitary stalk agenesis, empty sella, pituitary stalk agenesis or ectopic posterior pituitary “bright spot”
3) Short stature from Prader-Willi Syndrome
4) Short stature associated with chronic renal insufficiency (pre-transplantation)
5) History of intrauterine growth restriction who have not reached a normal height (≥ 2.25 SD below mean for age/gender) by age 2 years
6) Children with idiopathic short stature who are ≥ 2.25 SD below mean for height and are unlikely to catch up in height.
7) Turner’s syndrome or 45X, 46XY mosaicism
8) Hypoglycemia with evidence for hGH deficiency
9) SHOX deficiency (with genetic evidence for short stature homeobox-containing gene deficiency)
10) AIDS wasting syndrome (12 weeks therapy only.)
11) Other evidence for hGH deficiency submitted for panel review and decision

Transitional indications for clients on childhood hGH therapy (after reaching target height or epiphyseal closure$.)

Transitional patients must be phased down to adult hGH doses over a year.

1) Classic childhood hGH deficiency who fail an adult hGH stimulation tests after a month or more withholding hGH therapy.
2) Persons who have initiated growth hormone therapy in childhood because of pituitary damage, agenesis or anomaly.

Adult indications

1) Persons with other childhood indications for hGH therapy who fail an adult hGH stimulation test.
2) Persons who have initiated growth hormone therapy in childhood because of pituitary damage, agenesis or anomaly.
3) History of pituitary or hypothalamic injury due to tumor, trauma, surgery, irradiation, hemorrhage or infarction
   a. ≥ 3 pituitary hormones deficient and IGF-1 ≤ 2.5 percentile
   b. 0,1, or 2 hormones deficient and IGF-1 < 50th percentile failure of an adult growth hormone stimulation test as outlined below
4) AIDS wasting syndrome (12 weeks therapy only.)

FOR INITIATION OF hGH THERAPY
A member must be evaluated by an Endocrinologist, Pediatric Nephrologist, or an Infectious Disease Specialist before consideration will be given for coverage of Growth Hormone therapy.

The following information must be provided
- PROJECTED HEIGHT: final adult height without hGH therapy with hGH therapy
- TARGET HEIGHT: [Calculation – (Total of father’s and mother’s height in cm, divided by 2) plus 6.5cm for boys and minus 6.5cm for girls]
- COVERED HEIGHT - height to which coverage of hGH therapy will be provided [152.4cm for girls, 165.1cm for boys].

For continuation of hGH therapy
Client must be evaluated by an endocrinologist at least once a year, with monitoring for adverse effects and compliance and documentation of indications for continuation of therapy.

Contraindications to therapy
Presence of active malignancy or diabetes out of control or intracranial hypertension

Dose of hGH (doses must be individualized and titrated)
1) Children – 25 to 100 mcg/kg/day (in 3 to 7 doses per week) according to current pediatric guidelines.
2) Adults - 0.1 to 0.5 mg per day – lower doses in older clients. Doses should be evaluated and titrated at 1 to 2 month intervals targeting an IGF-1 level at or below the mean reference value for age and gender.

DIAGNOSIS OF CLASSIC hGH DEFICIENCY

A. Criteria for Initiation of Therapy
   Pediatric Members
   - Height below the third percentile on growth chart
   - Subnormal growth velocity: current height more than two standard deviations below the mean and/or growth velocity of less than 5cm/yr
   - Evidence of delayed bone age and open epiphysis.
   - No contributing medical condition, i.e. chronic diseases (cystic fibrosis, chronic renal failure), malnutrition, psychosocial deprivation, etc
   - Subnormal response of 10ng/ml or less on two provocative growth hormone stimulation tests
     Note: this criterion may be waived when a clinical diagnosis of panhypopituitarism, based on diagnostic radiographic and clinical findings (see below*) is made. In addition, children with a profoundly low growth velocity who are at high risk for GHD due to CNS radiation or other organic causes (termed “neurosecretory dysfunction”) may demonstrate “normal” responses to provocative tests, often for several years, yet often benefit from GH treatment. $

Panhypopituitarism is defined as a condition in which the secretion of anterior pituitary hormones, including growth hormone, is inadequate or absent. This condition can be acquired as a result of surgery or irradiation of the hypothalamus or pituitary, head trauma or central nervous system infections, or may be congenital. Furthermore,
radiological studies such as a MRI, may reveal pituitary stalk agenesis, empty sella, an underdeveloped anterior pituitary, or midbrain abnormalities that may indicate a diagnosis of GHD or multiple pituitary hormone deficiencies. These patients with organic GHD, or GHD secondary to major brain malformations tend to be the most profoundly deficient of all patients with GHD, and tend to have a very robust response to GH therapy. Many of these patients with multiple pituitary hormone deficiencies have severe hypoglycemia and seizures, and when treated with growth hormone, often have a dramatic response with rapid resolution of hypoglycemia. For these patients, a formal GH stimulation test usually is unnecessary in making the definitive diagnosis.

**Adult Members**
- Childhood or Adult onset of hGH deficiency
- Age < 60 years
- No evidence of active malignancy
- Other hormone deficiencies have been ruled out or stabilized with adequate replacement
- Subnormal response of 5ng/ml or less to insulin hypoglycemia growth hormone stimulation test

  Note, it is appropriate that the criteria for GHD in adults are much tighter, and stipulate the use of insulin.

  Most advocate that the max response should be less than 3 ng/ml, but some use 5....Bidingmaier M, Strasburger CJ. What endocrinologists should know about growth hormone Measurements. *Endocrinol Metab Clin North Am. Mar 2007;36(1):101-8.*

**B. Accepted Pharmacologic GH Stimulation Tests for children**
- Propranolol with exercise
- Levodopa
- Insulin hypoglycemia test
- Arginine HCl infusion
- Clonidine

  **Accepted childhood pharmacological hGH stimulation tests:**
  - Insulin tolerance test: 0.1 units per Kg insulin IV, with hGH samples at baseline and every 30 minutes to 120 minutes. hGH response of <10 ng/ml is evidence for hGH deficiency.$
  - OTHER (PENDING)

**Accepted adult pharmacological hGH stimulation tests:**
- Insulin tolerance test: 0.1 units per Kg insulin IV, with hGH samples at baseline and every 30 minutes to 120 minutes. hGH response of <5 ng/ml is evidence for hGH deficiency.
- Glucagon stimulation test: 1 mg glucagon IM with hGH samples at baseline and every 30 minutes to 180 minutes. hGH response of <3 ng/ml is evidence for hGH deficiency.

**C. Accepted GH Screening Test**
- Insulin-like growth factor 1 (IGF-1)
- Insulin-like growth factor – binding protein 3 (IGFBP-3)

**D. Continuation of Therapy**

**Pediatric Members**
- Members should be evaluated every 6 months to determine increase in growth velocity and monitor for adverse effects and compliance
- Client must be evaluated by an endocrinologist at least once a year, with monitoring for adverse effects and compliance and documentation of indications for continuation of therapy.
- Members should be evaluated every 4 months to determine growth velocity and monitor for adverse effects and compliance.

**Adult Members**
- Members should be evaluated every 6 months to monitor for adverse effects and compliance
E. Discontinuation of Therapy
Member therapy may be discontinued when one of the following criteria is met:

Pediatric Members
- Growth velocity less than 2.5cm/yr unless associated with another growth-limiting and treatable medical condition (i.e. hypothyroidism), and indicated by fused epiphyses by bone age determination.
- Covered height has been reached
- Inadequate compliance
- Significant adverse effects

Adult Members
- Inadequate compliance
- Significant adverse effects

DIAGNOSIS OF SHORT STATURE (INCLUDING PRADER-WILLI SYNDROME)

A. Initiation of Therapy
The member should meet three of the criteria listed:
- Delayed bone age and open epiphysis.
- Subnormal growth velocity: current height more than two standard deviations below the mean and/or growth velocity of less than 5cm/yr
  This needs to be modified, since newborns with congenital GHD will USUALLY have GV >>> 5 cm/year within the first few years of life, but still require treatment.
- Subnormal response of 10ng/ml or less on two provocative growth hormone stimulation tests
  “GH stimulation test responses are extremely poor in discriminating between normal and GHD children. This observation has led to a recommendation of the Stanford group (Wilson, et al. Journal of Pediatrics Oct 2003, 415-421) to declare GH stimulation tests as optional for prescribing therapy, especially in the context of growth failure, additional pituitary hormone deficiencies, and/or a history of surgery or irradiation in the region of the hypothalamus.”
- Projected height below Target height and Covered height

B. Continuation of Therapy
Members should be evaluated every six months to determine the increase in growth velocity. (See above)

C. Discontinuation of Therapy
Member therapy may be discontinued when one of the following criteria is met:
- Target height or Covered height has been reached
- Bone age of 15 or epiphyseal fusion for girls
- Bone age of 16 or epiphyseal fusion for boys
- Slow growth rate (< 5cm in the previous year) unless associated with another growth-limiting and treatable medical condition (i.e. hypothyroidism)
- Inadequate compliance
- Significant adverse effects

DIAGNOSIS OF SHORT STATURE ASSOCIATED WITH RENAL INSUFFICIENCY

A. Initiation of Therapy
The member should meet the following criteria:
- Documented chronic renal insufficiency with an estimated creatinine clearance less than 50ml/min
• Subnormal growth velocity: current height more than two standard deviations below the mean and/or growth velocity of less than 5cm/yr
• Projected height below Target height and Covered Height

B. Continuation of Therapy
Members should be evaluated every six months to determine the increase in growth velocity. (See above)

C. Discontinuation of Therapy
Member therapy may be discontinued when one of the following criteria is met:
• Target height or Covered height has been reached
• Bone age of 15 or epiphyseal fusion for girls
• Bone age of 16 or epiphyseal fusion for boys
• Slow growth rate (< 5cm in the previous year) unless associated with another growth-limiting and treatable medical condition (i.e. hypothyroidism) $
• Inadequate compliance
• Significant adverse effects
• Transplantation

DIAGNOSIS OF SMALL FOR GESTATIONAL AGE (SGA)

A. Initiation of Therapy
The member should meet the following criteria:
• Diagnosis of Small for Gestational Age
• Member over 2 years of age
• Subnormal growth velocity: current height more than two standard deviations below the mean and/or growth velocity of less than 5cm/yr
  Subnormal growth velocity: current height more than two standard deviations below the mean and/or growth velocity subnormal for age

B. Continuation of Therapy
Members should be evaluated every six months to determine the increase in growth velocity. (See above)

C. Discontinuation of Therapy
Member therapy may be discontinued when one of the following criteria is met:
• Target height or Covered height has been reached
• Bone age of 15 or epiphyseal fusion for girls
• Bone age of 16 or epiphyseal fusion for boys
• Slow growth rate (< 5cm in the previous year) unless associated with another growth-limiting and treatable medical condition (i.e. hypothyroidism) $
• Inadequate compliance
• Significant adverse effects

DIAGNOSIS OF TURNER’S SYNDROME OR 45X, 46XY MOSAICISM

A. Initiation of Therapy
The member should meet the following criteria:
• Chromosome analysis diagnosing either Turner’s syndrome in female members or 45X, 46XY mosaicism in males
• Height below the third percentile on growth charts
B. **Continuation of Therapy**
Members should be evaluated every six months to determine the increase in growth velocity. *(See above)*

C. **Discontinuation of Therapy**
Member therapy may be discontinued when one of the following criteria is met:

- Target height or Covered height has been reached
- Bone age of 15 or epiphyseal fusion for girls
- Bone age of 16 or epiphyseal fusion for boys
- Slow growth rate (< 5cm in the previous year) unless associated with another growth-limiting and treatable medical condition (i.e. hypothyroidism)
- Inadequate compliance
- Significant adverse effects

**DIAGNOSIS OF HYPOGLYCEMIA ASSOCIATED WITH hGH INSUFFICIENCY**

Hypoglycemia is a symptom that is present in some members as a result of low growth hormone levels. Because of the severity of problems related to this form of hypoglycemia (permanent neurologic morbidity, septo-optic dysplasia), it will be given separate consideration from short stature issues. Coverage will not be provided for growth hormone used to treat members with normal hGH levels who happen to be hypoglycemic.

A. **Initiation of Therapy**
Due to the severity of this condition, initial doses may be administered without receiving a medication coverage authorization first. However, appropriate information must be provided within 30 days for coverage consideration. When all member information has been received, a retroactive authorization will be given for any emergency doses dispensed.

B. **Continuation and Discontinuation of Therapy**
Members should be evaluated every six months to monitor for efficacy and side effects. Therapy should not be discontinued if there is a probability of the hypoglycemic condition reoccurring once hGH replacement therapy is withdrawn.

**DIAGNOSIS OF AIDS-RELATED WASTING SYNDROME (SEROSTIM ONLY)**

A. **Initiation of Therapy**
Members must have documentation showing that they fulfill all of the following criteria. Members meeting the criteria will be approved for an initial 4 week course of therapy.

- Unintentional weight loss of more than 10% if baseline pre-morbid weight was <120% of Ideal Body Weight OR unintentional weight loss of more than 20% if baseline pre-morbid weight was > 120% of Ideal Body Weight
- Member is receiving optimal antiretroviral therapy
- Member does not have a reversible cause of weight loss (e.g. infection, GI bleed or obstruction, or malnutrition)
- Member is receiving aggressive nutritional intake or supplementation
- Member does not have an active malignancy (except localized Kaposi’s Sarcoma)
- Member has had a poor response to therapy with megestrol acetate and/or dronabinol
- Male members have had serum testosterone levels evaluated and treated as needed

B. **Continuation of Therapy**
- At four weeks, the member will be evaluated for response to therapy (weight gain), side effects, and compliance. If member response is favorable, another 4 weeks of therapy will be authorized.
• Subsequent follow up evaluations will be required every 4 weeks to assess response, side effects, and compliance. The member may receive another 4 weeks of therapy for a maximum of 12 weeks of continuous therapy.

C. Discontinuation of Therapy
Therapy may be discontinued if the member meets any of the following criteria:

• Completion of the FDA approved 12 weeks of therapy
• Treatment failure as measured by EITHER no weight gain despite 8 weeks of therapy OR continued/resumed weight loss at any time following 8 weeks of therapy when other potential causes have been resolved or ruled out.
• Member non compliance
• Adverse effects that are refractory to dose reduction
• New or progressive Kaposi’s Sarcoma
• Member weight exceeds 110% of pre-morbid weight

DIAGNOSIS OF SHOX (short stature homeobox-containing gene) DEFICIENCY
The member should meet the following criteria:

• Chromosomel analysis diagnosing SHOX gene anomaly
• Height below the third percentile on growth chart
• Open epiphyses
• Normal endocrine screen
• No evidence of GH deficiency or insensitivity, tumor activity, diabetes mellitus, history of impaired glucose tolerance, or other serious illness known to interfere with growth

IGF-1 Analog Products
Inrelex™ and Iplex™ (mecasermin)

A. Initiation of therapy

• Therapy initiated by an endocrinologist
• Diagnosis of Primary IGF-1 Deficiency with all of the following:
  o Height >3 SD below the mean
  o Basal IGF-1 >3 SD below the mean
  o Normal or elevated GH
• Documentation of mutation in GH receptor (GHR) or mutation in post-GHR signaling pathway or IGF-1 gene defects (Laron Syndrome)
• Not approved for use in secondary IGF-1 deficiencies related to GH deficiency, malnutrition, hypothyroidism, or chronic steroid therapy.

B. Discontinue therapy
Therapy may be discontinued when one of the following criteria is met:

• Epiphyses closed
• Covered height (165.1 cm. in males, 152.4 cm in females) is reached
• Sensitivity to mecasermin
• Member is noncompliant
Questions for discussion by the Board regarding the current criteria:

**Diagnosis**

1) For the diagnosis of panhypopituitarism and growth hormone deficiency, should growth hormone continue to be covered into adulthood? $

2) Should growth hormone continue to be covered for idiopathic short stature as it currently is? $ If not, then what about short stature of chronic renal insufficiency, Prader-Willi, Turner’s syndrome, and Noonan’s syndrome?

3) At what age should GH therapy for short stature be initiated? $

4) At what age should GH therapy for growth hormone deficiency be initiated? $

5) Should the criteria be modified in the case of panhypopituitarism so that patients with multiple pituitary deficiencies, radiological evidence of absence of pituitary stalk or other pituitary abnormality, hx of irradiation, or surgery do not require stim testing?

6) Should the diagnosis of neurosecretory growth hormone deficiency be covered?

**Continuation**

1) Should continuation criteria include improvement parameters, e.g. 2 cm/yr improvement in growth velocity? Currently, criteria do not define required increase in growth velocity for continuation. Should a minimum acceptable increase in growth velocity be defined in the criteria for continuation of GH therapy?

**Discontinuing**

1) Should children with panhypopituitarism or GHD be allowed to stay on GH until their epiphyses seal (§) or until they reach covered height (165.1 cm (65”) for boys, 152.4 cm (60”) for girls)?

2) Should covered height be increased to 170.2 cm (67”) for boys? $

3) Should growth hormone for short stature of chronic renal insufficiency continue to be covered after kidney transplant? Currently, GH therapy is allowed to continue for these patients, even after the kidney transplant.

**Recommendation**

Since the FDA approved Norditropin for short stature of Noonan syndrome, the College also recommends adding Noonan syndrome as a covered indication. Criteria for this diagnosis would be the same as the other genetic disorders (Turner’s syndrome, 45X, 46XY mosaicism).
Fiscal Year 2010 Annual Review of Erythropoietin Stimulating Agents (ESAs)

Oklahoma Health Care Authority
October 2010

Current Prior Authorization Criteria for ESAs

1. FDA approved indication for specific products.
   a. Treatment of Anemia of Chronic Renal Failure Patients
   b. Treatment of Anemia in Zidovudine-treated HIV-infected Patients
   c. Treatment of Anemia in Cancer Patients on Chemotherapy
      i. Myelosuppressive Chemotherapy-Induced Anemia (Hb 8-10 g/dL) Non-Curative
   d. Reduction of Allogeneic Blood Transfusion in Surgery Patients

2. Most recent Hb levels (and date obtained) should be included on petition. Each approval will be for 8 weeks in duration. Authorization can be granted for up to 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen. Authorization for surgery patients will be for a maximum of 4 weeks.

3. Continuation Criteria:
   a. Continue dose if Hb is ≤ 12.0 g/dL.
   b. If Hb is increasing and approaching 12 g/dL then reduce dose by at least 25%.
   c. If more than 1 g/dL increase (but Hb not greater than upper limits listed below) has occurred in a 2 week period reduce dose by 25 to 50 %.

4. Discontinuation Criteria:
   a. ESRD – Discontinue treatment if Hb is at or above 13.0 g/dL.
   b. All others – Discontinue treatment if Hb is at or above 12 g/dL.
   c. If a minimum increase of 1 g/dL has not been achieved after initial 8 weeks of therapy.

5. Reinitiation Criteria:
   a. If Hb decreases to ≤ 10 g/dL then therapy may be reinitiated at 25 to 50% of the prior dose.

Trends in Utilization of ESAs

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Members*</th>
<th>Claims</th>
<th>Cost</th>
<th>Cost/ Claim</th>
<th>Units /Claim†</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>722</td>
<td>6,087</td>
<td>$2,406,084.46</td>
<td>$395.28</td>
<td>299.5</td>
</tr>
<tr>
<td>2009</td>
<td>597</td>
<td>7,835</td>
<td>$3,395,815.45</td>
<td>$433.42</td>
<td>205.3</td>
</tr>
<tr>
<td>2010</td>
<td>477</td>
<td>9,036</td>
<td>$2,262,697.86</td>
<td>$250.41</td>
<td>152.8</td>
</tr>
<tr>
<td>% Change‡</td>
<td>-20.1%</td>
<td>15.3%</td>
<td>-33.4%</td>
<td>-42.2%</td>
<td>-25.6%</td>
</tr>
<tr>
<td>Change†</td>
<td>-120</td>
<td>1,201</td>
<td>-$1,133,117.59</td>
<td>-$183.01</td>
<td>-52.5</td>
</tr>
</tbody>
</table>

*Some members may be duplicated between pharmacy and medical claims.
†Change from FY09 to FY10.
‡For medical billing only, does not include pharmacy claims.
Diagnoses for ESA Members during FY10

The majority of the claims for FY10 were for End Stage Renal Disease or a similar diagnosis (96.7%) followed by a cancer or chemotherapy related diagnosis (2.6%).

Age for Members Utilizing ESAs during FY10

![Age Distribution Bar Chart]

Prior Authorizations for FY 2010

The total number of petitions for this category was 1,954. A total of 1,445 were approved, 76 were denied, and 433 were incomplete.

![Prior Authorization Pie Chart]

Conclusions and Recommendations

Usage of these products appears to have continued to decline over the review period, based on both the available safety information and the use of the prior authorization. The increase in the number of claims appears to be related to a change in billing methods on the part of the providers who are billing more frequently.

The College of Pharmacy recommends continuation of the current ESA Prior Authorization criteria with the following change: increase the length of approval from eight weeks to 16 weeks per petition.
# Annual Review of Narcotic Analgesics and 30 Day Notice to Prior Authorize Butrans™, Primlev™, Xolo®X, Exalgo™ ER, Rybix™ ODT, and Suboxone®/Subutex®

**Oklahoma Health Care Authority**  
**October 2010**

## Current Prior Authorization Criteria

<table>
<thead>
<tr>
<th>Narcotic Analgesics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier-1 products are covered with no prior authorization necessary.</td>
</tr>
</tbody>
</table>

### Tier-2 Authorization Requires:
- documented 30 day trial/titration period with at least two Tier-1 medications within the last 90 days, or
- clinically appropriate pain therapy requiring time-released medication

### Tier-3 Authorization Requires:
- documented 30 day trial with at least two Tier-2 medications within the last 90 days, or
- documented allergy or contraindication to all Tier-2 medications

- Members with an oncology-related diagnosis are exempt from the prior authorization process, although quantity and dosage limits still apply. Actiq®, Fentora®, and Onsolis® are approved only for oncology-related diagnoses.
- Only one long-acting and one short-acting agent can be used concurrently.

<table>
<thead>
<tr>
<th>Tier-1</th>
<th>Tier-2</th>
<th>Tier-3</th>
<th>Oncology Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long Acting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fentanyl patch (DuraGesic®)</td>
<td>oxymorphone (Opana® ER)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>morphine ER</td>
<td>morphine sulfate (Kadian®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>morphine sulfate (Avinza®)</td>
<td>oxycodone (OxyContin®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tramadol ER (Ultram ER®, Ryzolt®)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>morphine and naltrexone (Embeda™)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short Acting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocodone/APAP (Xodol®, Zamicet™)</td>
<td></td>
<td>fentanyl (Actiq®, Onsolis™, Fentora®)</td>
<td></td>
</tr>
<tr>
<td>oxymorphone (Opana®)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tapentadol (Nucynta™)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
OTHER PRIOR AUTHORIZED ANALGESICS

Darvocet A500 (propoxyphene napsylate 100mg / acetaminophen 500mg)

Balacet 325 (propoxyphene napsylate 100mg / acetaminophen 325mg)
- Approved for members with documented need to restrict acetaminophen use or documented renal insufficiency or hepatic impairment.
- A quantity limit of 180/30 on each of the products also applies.

Hydrocodone/APAP
- Quantity limit for a maximum of 3,250mg of APAP per day.
- Annual claim limit of 12 per 365 days.
- Ingredient Duplication ProDUR edit for multiple claims from different physicians.

UTILIZATION FOR FISCAL YEAR 2010

TRENDS IN UTILIZATION

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Total Members*</th>
<th>Total Claims</th>
<th>Total Cost</th>
<th>Cost/ Claim</th>
<th>Cost/ Day</th>
<th>Total Units</th>
<th>Total Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>131,437</td>
<td>472,661</td>
<td>$16,844,634.14</td>
<td>$35.64</td>
<td>$2.54</td>
<td>30,537,055</td>
<td>6,634,981</td>
</tr>
<tr>
<td>2010</td>
<td>144,256</td>
<td>515,229</td>
<td>$17,243,745.82</td>
<td>$33.47</td>
<td>$2.29</td>
<td>33,668,641</td>
<td>7,544,467</td>
</tr>
<tr>
<td>% Change</td>
<td>9.8%</td>
<td>9.0%</td>
<td>2.4%</td>
<td>-6.1%</td>
<td>-9.8%</td>
<td>10.3%</td>
<td>13.7%</td>
</tr>
<tr>
<td>Change</td>
<td>12,819</td>
<td>42,568</td>
<td>$399,111.68</td>
<td>-2.17</td>
<td>-0.25</td>
<td>3,131,586</td>
<td>909,486</td>
</tr>
</tbody>
</table>

UTILIZATION DETAILS OF NARCOTIC ANALGESICS BY CLASS

<table>
<thead>
<tr>
<th>Class</th>
<th>Total Claims</th>
<th>Total Members</th>
<th>Total Cost</th>
<th>Claims/ Member</th>
<th>Cost/ Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocodone Combinations</td>
<td>292,342</td>
<td>82,481</td>
<td>$3,969,405</td>
<td>3.11</td>
<td>$0.98</td>
</tr>
<tr>
<td>Opioid Agonists</td>
<td>100,449</td>
<td>26,384</td>
<td>$10,467,061</td>
<td>3.81</td>
<td>$4.76</td>
</tr>
<tr>
<td>Opioid Combinations</td>
<td>45,945</td>
<td>25,435</td>
<td>$1,074,726</td>
<td>1.81</td>
<td>$1.96</td>
</tr>
<tr>
<td>Codeine Combinations</td>
<td>42,228</td>
<td>32,337</td>
<td>$360,633</td>
<td>1.31</td>
<td>$1.34</td>
</tr>
<tr>
<td>Propoxyphene Combinations</td>
<td>27,293</td>
<td>15,256</td>
<td>$259,383</td>
<td>1.79</td>
<td>$0.78</td>
</tr>
<tr>
<td>Opioid Partial Agonist</td>
<td>4,295</td>
<td>999</td>
<td>$1,036,986</td>
<td>4.30</td>
<td>$10.66</td>
</tr>
<tr>
<td>Tramadol Combinations</td>
<td>2,161</td>
<td>1,201</td>
<td>$52,756</td>
<td>1.80</td>
<td>$1.75</td>
</tr>
<tr>
<td>Dihydrocodeine Combinations</td>
<td>429</td>
<td>264</td>
<td>$18,584</td>
<td>1.63</td>
<td>$3.80</td>
</tr>
<tr>
<td>Pentazocine Combinations</td>
<td>87</td>
<td>41</td>
<td>$4,212</td>
<td>2.12</td>
<td>$3.02</td>
</tr>
</tbody>
</table>

| Total                  | 515,229      | 144,256*      | $17,243,746| 3.57           | $2.29     |

*Unduplicated Members
PRIOR AUTHORIZATION REQUESTS

Most prior authorization requests for this category are handled through the DUR Plus point-of-sale prior authorization system. There were a total of 4,108 manual petitions submitted for Narcotic Analgesics during Fiscal Year 2010. The following chart shows the status of the submitted petitions.

![Pie chart showing the status of the submitted petitions: 52% approved, 45% incomplete, and 3% denied.]

MARKET NEWS AND UPDATES

**BUTRANS™ (BUPRENORPHINE) TRANSDERMAL SYSTEM**

Butrans™ is indicated for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. The patch is worn continuously for 7 days. Butrans™ transdermal system comes in 5mcg/hour, 10mcg/hour, and 20mcg/hour. The maximum dose is 20mcg/hour.

**EXALGO™ (HYDROMORPHONE HCL) EXTENDED-RELEASE**

Exalgo™ is an opioid agonist indicated for once daily administration for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Exalgo™ tablets are available in 8mg, 12mg, and 16mg dosage strengths.

**PRIMLEV™ (OXYCODONE HCL/ACETAMINOPHEN)**

Primlev™ is an opioid analgesic combination medication used for relief of moderate to moderately severe pain. Primlev™ is an oblong shaped tablet that comes in three strengths: 5mg/300mg (yellow), 7.5mg/300mg (red), and 10mg/300mg (orange).
**XOLOX® (OXYCODONE HCL/ACETAMINOPHEN)**

Xolox® is an opioid analgesic combination medication used to relieve moderate to severe pain. Xolox® is available in 10mg/500mg tablet.

**RYBIX™ ODT (TRAMADOL HCL)**

Rybix™ ODT is indicated for the management of moderate to moderately severe pain in adults. It is a white orally disintegrating tablet with a mint flavor and is available only in 50mg.

**SUBOXONE® (BUPRENNORPHINE/ NALOXONE) AND SUBUTEX® (BUPRENNORPHINE) REVIEW**

According to package labeling, the use of these products in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements and have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe these products for the treatment of opioid dependence. These products are only FDA indicated for the treatment of opioid dependence. However, they are often used off-label for the treatment of pain. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), there are 81 certified physicians in Oklahoma and 8 treatment programs. A review of the Suboxone claims indicated that 85% of the claims were written by prescribers who are on the SAMHSA listing, however only a handful of the claims were processed by the pharmacies using the correct DEA number therefore it is difficult to tell from claims data whether the products are being used according to the FDA labeling. Medical claims data for the Suboxone members was also reviewed and 71% of the members had a diagnosis that indicated an addiction.

<table>
<thead>
<tr>
<th></th>
<th>SAMHSA Certified</th>
<th>Percent</th>
<th>Not SAMHSA Certified</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suboxone Claims</td>
<td>2,410</td>
<td>85%</td>
<td>419</td>
<td>15%</td>
</tr>
<tr>
<td>Prescribers</td>
<td>45</td>
<td>40%</td>
<td>67</td>
<td>60%</td>
</tr>
</tbody>
</table>

Several states and insurance plans currently have criteria in place for the use of these medications. Some of the surrounding states’ criteria are listed below.

**Arkansas:** Requires an ICD-9 for opioid dependence and also has quantity limits in place. Subutex is approved for induction only and no other opioids may be prescribed for members.

**Kansas:** Requires a copy of the SAMHSA waiver confirmation and diagnosis of opioid dependence.
**Missouri:** Clinical edit in place which requires an appropriate diagnosis before approval and physician with SAMHSA waiver.

**Colorado:** Requires a prior authorization and must be for opioid dependency. Physician must have a waiver and the maximum dose is 24 mg daily.

**Texas:** No prior authorization, but is a part of the opiate overutilization clinical edit.

---

**CONCLUSION AND RECOMMENDATIONS**

---

**SUBOXONE®/SUBUTEX® RECOMMENDATIONS**

The College of Pharmacy recommends all prescriptions for Suboxone® (buprenorphine/naloxone) tablets and film or Subutex® (buprenorphine), and their generic equivalents if available, require prior authorization.

Criteria for coverage are as follows:

- Prescribed by a licensed physician who qualifies for a waiver under the Drug Addiction Treatment Act (DATA) and has notified the Center for Substance Abuse Treatment of the intention to treat addiction patients and has been assigned a DEA (X) number.
- Diagnosis of opiate abuse/dependence.
- Combination with benzodiazepines, hypnotics, and opioids (including tramadol) will be denied.
- Approval will be for 90 days to allow for concurrent medication monitoring.
- The following limitations will apply:
  - **Suboxone®** 2mg/0.5mg and 8mg/2mg tablets and film: A quantity limit of 90 per 30 days.
  - **Subutex®** 2mg tablets and 8mg tablets for induction only: a quantity limit of 15 tablets for up to a 5 day supply allowed (if the member is pregnant, product may be used for the duration of the pregnancy).

---

**NEW TIER RECOMMENDATIONS**

The College of Pharmacy recommends continuation of the Narcotic PBPA Category. In addition, the College of Pharmacy recommends placement of the following products in the current Tier structure:

**Butrans™:** to be placed in Tier 3 of the long-acting products Tier structure, with a quantity limit of 4 patches every 28 days.
**Exalgo**: to be placed in Tier 3 of the long-acting products Tier structure, with a quantity limit of 1 tablet daily for the 8mg, 3 tablets daily for the 12mg, and 4 tablets daily for the 16mg.

**Primlev™ and Xolox**: to be placed in Tier 3 of the short-acting products Tier structure, with a quantity limit based on 3,250 mg of acetaminophen daily and a clinical reason why member cannot use currently available similar generic products.

**Rybix™ ODT**: to be placed in Tier 3 of the short-acting products Tier structure, with a quantity limit of 4 tablets per day and a diagnosis indicating the member has a condition that prevents them from swallowing tablets.

Additionally, the College recommends moving the hydrocodone/APAP products, Xodol® and Zamicet™, from Tier 2 to Tier 3 with additional criteria requiring a clinical reason why the member cannot use currently available similar generic products. The College also recommends that any brand-only formulations of currently available generic narcotic products be placed in Tier 3 with similar criteria.

<table>
<thead>
<tr>
<th>Narcotic Analgesics</th>
<th>Tier-1</th>
<th>Tier-2</th>
<th>Tier-3</th>
<th>Oncology Only</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Long Acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All immediate release narcotics not listed in a higher tier</td>
<td>fentanyl patch (Duragesic*)</td>
<td>oxymorphone (Opana® ER)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>morphine ER</td>
<td>morphine sulfate (Kadian®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>morphine sulfate (Avinza®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>oxycodone (OxyContin®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>tramadol ER (Ultram ER®, Ryzolt®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>morphine and naltrexone (Embeda™)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>buprenorphine transdermal (Butrans™)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hydromorphone (Exalgo™)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short Acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxymorphone (Opana®)</td>
<td>tramadol ODT (Rybix™)</td>
<td>fentanyl (Actiq®, Onsolis™, Fentora®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tapentadol (Nucynta™)</td>
<td>oxycodone/APAP (Primlev™, Xolox®)</td>
<td>hydrocodone/APAP (Xodol®, Zamicet™)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>